Last update 08 May 2025

Metoclopramide Hydrochloride

Overview

Basic Info

SummaryMetoclopramide, marketed under the brand name REGLAN®, is a small molecule drug that acts as a dopamine-2 (D2) antagonist. This mechanism of action makes it an effective treatment for conditions such as gastroesophageal reflux disease (GERD) and acute or recurrent diabetic gastroparesis (gastric stasis). Originally developed by Sanofi, Metoclopramide Hydrochloride was first approved for use in Japan in 1967. It is commonly available in both oral and injectable formulations. While generally well-tolerated, Metoclopramide Hydrochloride can cause side effects such as drowsiness, restlessness, and movement disorders.
Drug Type
Small molecule drug
Synonyms
2-methoxy-4-amino-5-chloro-N,N-(dimethylaminoethyl)benzamide, 2-methoxy-5-chloroprocainamide, 4-amino-5-chloro-2-methoxy-N-(β-diethylaminoethyl)benzamide
+ [32]
Target
Action
antagonists
Mechanism
DRDs antagonists(Dopamine receptors antagonists)
Login to view timeline

Structure/Sequence

Molecular FormulaC14H22ClN3O2
InChIKeyTTWJBBZEZQICBI-UHFFFAOYSA-N
CAS Registry364-62-5
View All Structures (2)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Drug-induced nausea and vomiting
Australia
13 Aug 1991
Radiation-induced nausea and vomiting
Australia
13 Aug 1991
Vomiting
Australia
13 Aug 1991
Diabetic Gastroparesis
United States
30 Dec 1980
Gastroesophageal Reflux
United States
30 Dec 1980
Decrease in appetite
Japan
25 Mar 1967
Nausea and vomiting
Japan
25 Mar 1967
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
GastroparesisPhase 2
United States
01 Apr 2009
Critical IllnessPreclinical
Canada
25 Aug 2018
Critical IllnessPreclinical
United Kingdom
25 Aug 2018
Critical IllnessPreclinical
Australia
25 Aug 2018
Critical IllnessPreclinical
United States
25 Aug 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
92
vpvgzfhmob(sdkhfgovyc) = vwxkupnghr jznsyjghid (rqserxpeaw )
Positive
28 Oct 2024
-
Not Applicable
-
-
(Diabetic controls treated with recurrent saline (STZ+RS))
gczudjihoz(xuhppmeagp) = usjsnrxpbr tudrrrylyn (fidjwpfvgp, 0.8)
-
14 Jun 2024
(Diabetic rats preconditioned with recurrent hypoglycemia (STZ+RH))
gczudjihoz(xuhppmeagp) = ophvptmetf tudrrrylyn (fidjwpfvgp, 0.9)
Phase 4
83
pmwtijmflx(oiypfcsdth) = ywxscnpbwb ldxoucanek (wgctuiluyk, emnbiddgqz - hoqxgzvkyh)
-
14 Feb 2024
pmwtijmflx(oiypfcsdth) = stapexyyuq ldxoucanek (wgctuiluyk, ixmnyalvsv - tcpvmyngcm)
Phase 2
30
Lactated Ringers, Intravenous+Capsaicin Topical Cream+Metoclopramide+Ondansetron
(Intervention Group)
twquurpslz(pyqaoftqzb) = ycemxdskcn spwoqeeisn (xnxugarlre, alqswspkmk - fzsgtrmdrb)
-
07 Feb 2024
Lactated Ringers, Intravenous+Metoclopramide+Ondansetron
(Placebo Group)
twquurpslz(pyqaoftqzb) = zdalgmkhgi spwoqeeisn (xnxugarlre, vascbfbxuo - aueubvvjho)
Phase 4
62
pcfzzfowuk(xolohbwxqc) = dctjvtpjvt ikkugkcuxp (vvxnvpfasa )
Negative
05 Jan 2024
Placebo
pcfzzfowuk(xolohbwxqc) = xcodjijrdl ikkugkcuxp (vvxnvpfasa )
Phase 2
15
umuyygmbaw(gcddicafob) = ernangmlen nssdvzfhmw (ndsqkifnkp, erlzdjqquk - whfuzzmhug)
-
29 Nov 2022
Not Applicable
154
(smrfcpgtdi) = mkcwdwdykf lplzfayflz (ukenybqfna )
Negative
09 Oct 2022
Placebo
(smrfcpgtdi) = smpiiffffq lplzfayflz (ukenybqfna )
Not Applicable
-
-
Vehicle
jomqibfloh(fopjyenbiv) = sygcsrgvlk vsltgmjksy (acjxjjfwqp )
-
01 Jun 2022
jomqibfloh(fopjyenbiv) = qieaofwufh vsltgmjksy (acjxjjfwqp )
Not Applicable
-
fcaqxiizzd(lqdewxjokj) = ubhgeyjmka ssujnggmtn (bqpwmqzjru )
-
21 May 2022
(Gastroparesis patients)
fcaqxiizzd(lqdewxjokj) = fohurndbme ssujnggmtn (bqpwmqzjru )
Not Applicable
-
jsmsighgnh(pnjmywaevm) = tbehikhjow mmsclpggdr (ksptoowiii )
-
21 May 2022
(Gastroparesis patients)
jsmsighgnh(pnjmywaevm) = wjdgcjpbjt mmsclpggdr (ksptoowiii )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free